CEO & Co-Founder Speaking at the CEO Roundtable Panel

USA - English

Dose in the Valley Program

VANCOUVER, Feb. 20, 2018 /PRNewswire/ - Precision NanoSystems (PNI) is honored that our CEO & Co-Founder, James Taylor, was asked by the Consulate General of Canada to speak during the CEO Roundtable Panel at the upcoming Dose in the Valley Program Conference scheduled for February 21-22, 2018.

Tales from the Battle Ground CEO Roundtable | Joanne Fedeyko, CEO, Connection Silicon Valley (Moderator) | James Taylor, Ph.D. CEO, Precision NanoSystems | Giles Ochs, Co-Founder Prospect Bio
Date: Wednesday, February 21st Time: 8:50 am – 9:55 am
Location: Wilson Sensini Goodrich & Rosati 1 Market St #1900 - San Francisco, CA 94105.

"I look forward to sharing the PNI story and the lessons learned from the early days of start-up to the challenges of a growing company" said James Taylor, CEO & Co-Founder PNI. "We have achieved some major milestones over the past year with over 200 systems deployed in 20 countries, 11 of the top 15 pharma using the NanoAssemblr platform™ and PNI technology featured in over 90 peer reviewed publications. The strong growth of both our company and customer-base highlights the potential of the NanoAssemblr platform, and our commitment to continually transform nanomedicine technologies."

About Dose of the Valley
A two-day Life Sciences event and includes roundtable discussions, industry-led workshops, one-on-one mentorship, an investor/partnering pitch session, and networking. This is a unique opportunity for innovative Canadian companies to engage with industry contacts who will be mentors, speakers, and panelists. Up to 20 companies will be selected for the program. Life sciences companies focused on biotech, med tech, digital health, imaging and diagnostics are invited to apply.

About Precision NanoSystems, Inc.
Precision NanoSystems Inc. (PNI) creates innovative solutions for the discovery, development and manufacture of novel nanoparticles for use as medicines and in medical research. PNI's proprietary NanoAssemblr Platform enables the rapid, reproducible, and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body. PNI provides instruments, reagents and services to life sciences researchers, including pharmaceutical companies, and builds strategic collaborations to revolutionize healthcare through nanotechnology. For more information, visit www.precisionnanosystems.com.

SOURCE Precision Nanosystems